Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer
Stock Information for Avalon GloboCare Corp.
Loading
Please wait while we load your information from QuoteMedia.